SCHEMBL4067717

SCHEMBL4067717

Cc1cccc(-c2cc3ncnc(NCCc4c[nH]c5ccccc45)c3s2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 5/20 0.54
EGFR P00533 3/20 0.54
LMNA P02545 6/20 0.51
MAPT P10636 3/20 0.51
MAPK1 P28482 3/20 0.51
HTT P42858 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
GFER P55789 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
USP2 O75604 5/20 0.48
CYP1A2 P05177 5/20 0.48
CYP3A4 P08684 5/20 0.48
CYP2D6 P10635 5/20 0.48
CYP2C9 P11712 5/20 0.48
CYP2C19 P33261 5/20 0.48
CLK4 Q9HAZ1 5/20 0.48
KMT2A Q03164 4/20 0.48
MEN1 O00255 3/20 0.48
HIF1A Q16665 2/20 0.48
TP53 P04637 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4251177 0.95 FLT1 (0.51) FLT1EGFRLMNAMAPTMAPK1
SCHEMBL3927158 0.88 CYP1A2 (0.63) FLT1EGFRLMNAMAPTMAPK1
SCHEMBL3929003 0.87 LMNA (0.49) FLT1EGFRLMNAMAPTMAPK1
SCHEMBL3938271 0.87 TYK2 (0.54) FLT1EGFRLMNAMAPTMAPK1
SCHEMBL4070516 0.86 PDPK1 (0.52) FLT1EGFRLMNAMAPTMAPK1
SCHEMBL4076692 0.85 CYP1A2 (0.55) FLT1EGFRLMNAMAPTMAPK1
SCHEMBL3937311 0.85 STK17B (0.53) FLT1EGFRLMNAMAPTMAPK1
SCHEMBL3936979 0.85 CYP1A2 (0.59) FLT1EGFRLMNAMAPTMAPK1
SCHEMBL4066406 0.84 LMNA (0.53) FLT1EGFRLMNAMAPTMAPK1
SCHEMBL3936707 0.83 FLT1 (0.46) FLT1EGFRLMNAMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor BAYER SCHERING PHARMA AG (DE) 2009-02-12 US claimed
EP-2014662-A1 Indolyl alkyl thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma Aktiengesellschaft (DE) 2009-01-14 EP claimed
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor BAYER SCHERING PHARMA AG (DE) 2009-02-12 US disclosed
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor BAYER SCHERING PHARMA AG (DE) 2009-02-12 US disclosed
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor BAYER SCHERING PHARMA AG (DE) 2009-02-12 US disclosed
EP-2014662-A1 Indolyl alkyl thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma Aktiengesellschaft (DE) 2009-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor PTGER2, PTGER1, PTGDR2 FLT1 3775/4885EGFR 498/4885LMNA 2915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.